Schedule 1 is for substances without medical merit, addictive, and likely to be abused. In other words, medically useless and dangerous. Shortly before this recent CBD event, the DEA refused to remove cannabis or marijuana from its existing Schedule 1 position, deferring to the FDA’s medical evaluation.
Bureaucratic Resistance Increases as Medical Use and Popularity for Cannabis Expands
The DEA’s wording of its recent decision on CBD extracts or oils included the following defining phrase of positioning as Schedule 1 any “… extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis.”
Prior to this, any cannabis extract generally with less than .03 percent THC content was considered okay medicinally. Three percent THC is allowed for industrial hemp products imported from Canada, China, and the EU, and is now being grown experimentally in some states in the U.S., such as Kentucky.
Most of us know these recent DEA declarations are simply false, not even close to true. On the other hand, the pharmaceutical industry is putting its versions of synthetic CBD through trials while synthetically produced THC derivatives are already in the market. THC is a major cannabinoid that produces the “high,” while CBD is the other major medicinal cannabinoid that does not have psychotropic effects.
Because CBD does not produce any psychotropic effects, and yet is effective for several medical issues, most notably epileptic seizures, it has been allowed for children with epilepsy even in some states that do not permit full plant cannabis with THC medically.
Yet now the DEA says it’s as medically useless and dangerous as heroine.
Read more at Health Impact News..